Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered question first ministerially corrected answering member label previous answer version answering member printed answering member label
tabling member	label

Search

1657663

registered interest
date	04/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Safety
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the quality and safety of (1) imported, and (2) home produced generic drugs; and whether they plan to step up testing following the decision of the US military to introduce a new testing programme.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9752
answer	answer is ministerial correction date of answer 13/09/2023 answer text <p>Before a medicine can be placed onto the market in the United Kingdom, it must first receive approval from the Medicines and Healthcare products Regulatory Agency (MHRA) via the granting of a Marketing Authorisation, commonly known as a product licence. Each medicinal product is assessed for its safety, quality, and efficacy. For a generic medicine, an assessment of whether the medicinal product is equivalent to the proprietary medicine will also be performed.</p><p>Manufacturers of all medicines, including generics, are required to perform testing for each batch before it is released to market to ensure that it meets the specifications as set out in the product licence. There are currently no plans to amend these testing processes. If the UK product is manufactured in a third country there is an additional requirement for testing after importation i.e., after shipping, but before release to the market. This extra control measure is not a requirement for supply to the market in the United States of America.</p><p>It should be noted that medicines, including generics, must comply with the same Good Manufacturing Standards which are applicable for domestic and third country manufacturers. The MHRA’s medicines inspectorate conduct inspections to ensure that those manufacturing medicines meet these stringent Good Manufacturing Practice standards. These standards are also applicable to the testing facilities, which are also the subject of inspections to ensure the appropriate standards are being met.</p> answering member printed Lord Markham question first answered 13/09/2023 13:45:45 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1655027

registered interest
date	24/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Safety
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the potential of human-specific technologies, such as liver-on-a-chip, to improve the accuracy of tests to ascertain the safety of new drugs in humans.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9600
answer	answer is ministerial correction date of answer 31/07/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is aware of human-specific technologies, including organ-on-chip technologies, to better identify potential toxicity and safety of novel medicines and has engaged with other organisations active in this space such as the National Centre for the Replacement, Refinement &amp; Reduction of Animals in Research which has hosted meetings on this theme. The MHRA has also provided scientific advice to at least one biotechnology company on the use of this technology to support proof of concept for a new medicine. The MHRA does not identify those with whom it may have had discussions who are active commercially in this space.</p><p>In relation to human specific methods, some medicines have been developed which only have activity in humans, such as eculizumab (Soliris), tebentafusp (Kimmtrak) or CAR T cell products (for instance, Kymriah, Yescarta and Tecartus). These medicines were developed using human specific methods; however, versions of these medicines that were active in animals were, in some cases, also used. The MHRA supports the developers of these products by its offer of scientific advice services, the Innovation Office and the Innovative Licensing and Access Pathway.</p> answering member printed Lord Markham question first answered 31/07/2023 14:48:48 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1655069

registered interest
date	24/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Closures
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to deal with the closure of care homes for older people due to rising interest rates.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9602
answer	answer is ministerial correction date of answer 01/08/2023 answer text <p>Under the Care Act 2014, local authorities are required to ensure that people have a range of high-quality, sustainable, and person-centred care available to them, and that they can access the services that best meet their needs. This includes ensuring that, where providers exit the market, care provision is maintained with minimum disruption. The Government recognises the pressures faced by the adult social care sector, including rising interest rates, and is making available up to £7.5 billion of additional funding over two years to support adult social care and discharge. We expect local authorities to use the additional funding available for social care to go beyond meeting inflationary pressures, including those experienced in 2022/23.</p> answering member printed Lord Markham question first answered 01/08/2023 09:36:00 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1655071

registered interest
date	24/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Infant Foods: Labelling
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the accuracy and compliance of baby milk powder labels with regulatory requirements.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9604
answer	answer is ministerial correction date of answer 01/08/2023 answer text <p>Legislation requires that notification be given to the “competent authority” when infant formulae are placed on the market in Great Britain for the first time. The competent authority in this respect means the Secretary of State for Health and Social Care.</p><p>The Department is centrally coordinating notification forms for all three of England, Scotland, and Wales. Northern Ireland requires separate notification under the requirements of the European Union legislation that is directly applicable there. A copy of the label is required along with any other information that may reasonably be requested to establish compliance. Where areas of potential non-compliance are seen, such as mandatory statements being omitted, these are raised with the company. As each product has a unique label, they are assessed on an individual basis. Enforcement of this legislation in England is the responsibility of local authorities.</p> answering member printed Lord Markham question first answered 01/08/2023 15:40:25 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1654937

registered interest
date	20/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: Coronavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what percentage of the overall material and medical equipment installed in Nightingale Hospitals around the country, and specifically in Middlesbrough, has been redirected to (1) other NHS facilities, (2) to social care, or (3) to other uses; and what percentage has been sent to landfill, incineration and for recycling.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9534
answer	answer is ministerial correction date of answer 01/08/2023 answer text <p>The information requested is not held centrally. A Nightingale hospital was not established in Middlesbrough.</p><p>NHS England advises that each trust that hosted a Nightingale hospital is responsible for managing the assets and equipment therefrom including beds and medical equipment. Some of these will have been utilised by trusts hosting the Nightingale hospitals. The remaining surplus stock has been collected and made available for national redistribution under the existing warehousing, asset tracking and logistics contracts.</p><p>Minimal waste will be generated from this process, for example, some stock was perishable and unable to be used beyond use-by dates. Where items for disposal have been identified the responsible organisation will ensure this stock is recycled or used to create an energy source from waste, in compliance with national policy on waste disposal.</p> answering member printed Lord Markham question first answered 01/08/2023 15:39:33 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1652128

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what discussions they have had with the government of Japan about bilateral collaboration into research into new antimicrobial agents and antimicrobial drugs.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9232
answer	answer is ministerial correction date of answer 17/07/2023 answer text <p>We are working closely with Japan to promote research into novel antimicrobial products and to address the global market failures in antibiotic research and development. Professor Dame Sally Davies, the United Kingdom Special Envoy on Antimicrobial Resistance (AMR), visited Japan earlier this year and met with parliamentarians, senior officials and industry leaders to highlight the threat posed by AMR and to share experiences from the world-leading NHS England and National Institute for Health and Care Excellence antimicrobial reimbursement project.</p><p>Officials at the Department of Health and Social Care and the Foreign, Commonwealth and Development Office continue to have bilateral consultations with their Japanese counterparts on national research into new antimicrobial agents and UK Ministers also highlighted the importance of this during G7 Ministerial meetings. Collaboration on AMR also continues between UK Research and Innovation and the Japan Agency for Medical Research and Development under the Memorandum of Cooperation.</p> answering member printed Lord Markham question first answered 17/07/2023 16:57:31 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1652131

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prisoners: Foetal Alcohol Syndrome
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what work is being done in prisons to identify victims of Foetal Alcohol Syndrome; and what steps they are taking to introduce appropriate management and treatment regimes for those prisoners identified.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9235
answer	answer is ministerial correction date of answer 20/07/2023 answer text <p>All people in prison receive an early health assessment through a reception screening process. Every person receives a first and second stage health assessment, which incorporates a mental health screening in line with National Institute for Health and Care Excellence guidelines. This screening includes questions and actions relating to their risk of self-harm and/or suicide, learning disabilities and neurodevelopmental disorders.</p><p>For women who are pregnant and in prison, a full health assessment is undertaken. Any risks, such as alcohol dependency which could lead to foetal alcohol spectrum disorder (FASD), should be monitored and managed by the healthcare team, including midwife support. Currently there is no specific treatment for FASD, but where a baby is at risk of FASD, this will form part of the birth plan with the hospital.</p> answering member printed Lord Markham question first answered 20/07/2023 15:54:33 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1651487

registered interest
date	10/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Standards
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the level of support available under the Pharmacy Access Scheme; and whether the criteria includes the (1) quality, (2) opening hours, and (3) range of provision, of existing pharmacies.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL9200
answer	answer is ministerial correction date of answer 19/07/2023 answer text <p><del class="ministerial">The early access to medicines scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.</del></p><p><del class="ministerial">Under the scheme, the Medicines and Healthcare products Regulatory Agency (MHRA) will give a scientific opinion on the benefit/risk balance of the medicine, based on the data available when the EAMS submission was made and the EAMS criteria. The MHRA will make an evaluation of products, including drugs such as for brain tumour treatments, once an application is received.</del></p><p><del class="ministerial">If we do receive an application, it is only made public where an EAMS Scientific Opinion (SO) is awarded. All EAMS SOs are published on the EAMS webpage. All drugs that have previously held an EAMS SO are also published on the EAMS webpage.</del></p><p><ins class="ministerial">The Pharmacy Access Scheme provides additional funding to pharmacies where the next nearest pharmacy is more than a 20-minute walk away. This is calculated as a 0.8-mile walking distance in areas of high deprivation and 1 mile in other areas. In 2021, we agreed updated eligibility criteria and an updated payment model with Community Pharmacy England. To be eligible for the payment, pharmacies must deliver the Community Pharmacist Consultation Service. Quality and opening hours are not included in the eligibility criteria.</ins></p><p> </p><p> </p> answering member printed Lord Markham question first answered 19/07/2023 15:05:50 question first ministerially corrected 20/07/2023 15:18:01 answering member 4948 label Biography information for Lord Markham previous answer version 88780 answering member printed Lord Markham answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1648704

registered interest
date	28/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Zoonoses
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the finding of Min Cui, Bang Shen and others in their article ‘Animal diseases and human future’, published in Animal Diseases in April 2022, that 75 per cent of emerging human infectious diseases originate from animals.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL8865
answer	answer is ministerial correction date of answer 10/07/2023 answer text <p>UK Health Security Agency (UKHSA) is aware of the paper Animal diseases and human future by Min Cui, Bang Shen et al published in Animal Diseases, April 2022. The paper asserts that “approximately 60% of human infectious diseases are zoonotic, and 75% of emerging human infectious diseases originate from animals”. While there is not one internationally agreed figure for the percentages of diseases, emerging or established, that are zoonotic, these figures are broadly in line with that of global public health partners such as World Organisation for Animal Health.</p> answering member printed Lord Markham question first answered 10/07/2023 14:28:26 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle

1648323

registered interest
date	27/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Urinary Tract Infections
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether they have plans for trials across England of antibiotic cessation for those receiving prophylactic antibiotics for recurrent urinary tracts infection, as pioneered in Wales.
tabling member printed	Baroness Bennett of Manor Castle
uin	HL8808
answer	answer is ministerial correction date of answer 05/07/2023 answer text <p>NHS England has supported two integrated care boards (ICBs) in the East of England to pilot local schemes to incentivise primary care networks to identify patients prescribed prophylactic antibiotics and invite those patients for a clinical review. Prescribing data will be used to monitor the impact of these pilot schemes and, if safe and effective, underpin a national roll out of this approach.</p> answering member printed Lord Markham question first answered 05/07/2023 16:20:58 answering member 4948 label Biography information for Lord Markham
tabling member	4719 label Biography information for Baroness Bennett of Manor Castle